BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Endometrial Cancer
Interventions
DRUG

BKM120

NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Utah

OTHER